301 related articles for article (PubMed ID: 19439919)
1. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
Arnold AW; Bruckner-Tuderman L; Zuger C; Itin PH
Dermatology; 2009; 219(1):80-3. PubMed ID: 19439919
[TBL] [Abstract][Full Text] [Related]
2. Squamous cell carcinoma complicating epidermolysis bullosa in a 6-year-old girl.
Shivaswamy KN; Sumathy TK; Shyamprasad AL; Ranganathan C
Int J Dermatol; 2009 Jul; 48(7):731-3. PubMed ID: 19570079
[TBL] [Abstract][Full Text] [Related]
3. Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa-Hallopeau-Siemens: a report of four cases.
Dammak A; Zribi J; Boudaya S; Mseddi M; Meziou TJ; Masmoudi A; Ellouze Z; Keskes H; Turki H
Int J Dermatol; 2009 Jun; 48(6):588-91. PubMed ID: 19538366
[TBL] [Abstract][Full Text] [Related]
4. A 13-year-old girl with recessive dystrophic epidermolysis bullosa presenting with squamous cell carcinoma.
Ayman T; Yerebakan O; Ciftçioglu MA; Alpsoy E
Pediatr Dermatol; 2002; 19(5):436-8. PubMed ID: 12383103
[TBL] [Abstract][Full Text] [Related]
5. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
[No Abstract] [Full Text] [Related]
6. Reduced expression of insulin-like growth factor-binding protein-3 (IGFBP-3) in Squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa.
Mallipeddi R; Wessagowit V; South AP; Robson AM; Orchard GE; Eady RA; McGrath JA
J Invest Dermatol; 2004 May; 122(5):1302-9. PubMed ID: 15140235
[TBL] [Abstract][Full Text] [Related]
7. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
8. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
Kivisaari AK; Kallajoki M; Mirtti T; McGrath JA; Bauer JW; Weber F; Königová R; Sawamura D; Sato-Matsumura KC; Shimizu H; Csikós M; Sinemus K; Beckert W; Kähäri VM
Br J Dermatol; 2008 Apr; 158(4):778-85. PubMed ID: 18284387
[TBL] [Abstract][Full Text] [Related]
9. Treatment of skin cancers in epidermolysis bullosa.
Venugopal SS; Murrell DF
Dermatol Clin; 2010 Apr; 28(2):283-7, ix-x. PubMed ID: 20447493
[TBL] [Abstract][Full Text] [Related]
10. [Role of cutaneous pinch grafts in the healing of patients with dystrophic epidermolysis bullosa wounds: report of four cases].
Claude O; Binder JP; Bustamante K; Blanchet-Bardon C; Andrivon F; Revol M; Servant JM
Ann Chir Plast Esthet; 2005 Jun; 50(3):189-96. PubMed ID: 15963838
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and Outcome of Squamous Cell Carcinoma in Epidermolysis Bullosa in Australia and New Zealand.
Kim M; Li M; Intong-Wheeler LRA; Tran K; Marucci D; Murrell DF
Acta Derm Venereol; 2018 Jan; 98(1):70-76. PubMed ID: 28853495
[TBL] [Abstract][Full Text] [Related]
12. Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa.
Rokunohe A; Nakano H; Aizu T; Kaneko T; Nakajima K; Ikenaga S; Matsuzaki Y; Murai T; Tamai K; Sawamura D
J Dermatol; 2008 Jun; 35(6):336-40. PubMed ID: 18578710
[TBL] [Abstract][Full Text] [Related]
13. Inherited epidermolysis bullosa dystrophica and squamous cell carcinoma- A case report.
Gayathri E; Anbukkarasi K; Lilly SM
Indian J Pathol Microbiol; 2023; 66(2):360-362. PubMed ID: 37077084
[TBL] [Abstract][Full Text] [Related]
14. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.
Kivisaari AK; Kallajoki M; Ala-aho R; McGrath JA; Bauer JW; Königová R; Medvecz M; Beckert W; Grénman R; Kähäri VM
Br J Dermatol; 2010 Oct; 163(4):726-35. PubMed ID: 20586780
[TBL] [Abstract][Full Text] [Related]
16. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
17. Electrochemotherapy, a local treatment for squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Bartolo J; Farricha V; Carvalhal S; Moura C; Abecasis N
Dermatol Ther; 2020 Nov; 33(6):e14093. PubMed ID: 32720460
[TBL] [Abstract][Full Text] [Related]
18. MMP13 can be a useful differentiating marker between squamous cell carcinoma and benign hyperkeratotic lesions in recessive dystrophic epidermolysis bullosa.
Hata H; Abe R; Suto A; Homma E; Fujita Y; Aoyagi S; Shimizu H
Br J Dermatol; 2015 Mar; 172(3):769-73. PubMed ID: 25066310
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: results of a phase 1 trial of systemic isotretinoin.
Fine JD; Johnson LB; Weiner M; Stein A; Suchindran C
J Am Acad Dermatol; 2004 Apr; 50(4):563-71. PubMed ID: 15034505
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
